clinical trial · NCT07589595
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
Eli Lilly and Company·phase2·not yet recruiting·n = 350
Cognitive DysfunctionLewy Body DiseaseSynucleinopathiesAmyloidDonanemabPlacebo
brief summary
The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily activities) decline. For each participant, the study will last one and a half years.
started
May 1, 2026
primary completion
Aug 1, 2028
completion
Aug 1, 2028
last updated
May 15, 2026
official title
A Phase 2 Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Donanemab in Participants With Early Cognitive Decline, at Least One Core Clinical Feature of Dementia With Lewy Bodies, and Confirmation of Alpha-Synuclein and Amyloid Co-pathology
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol